Monday November 19, 2018 06:26

Heathcare Press Release : 25 Jun 2018

Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Heathcare—25 Jun 18

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used Heathcare—25 Jun 18

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Heathcare—25 Jun 18

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)

Ozempic(R) Provided Greater Weight Reductions for Adults With a Baseline BMI ?25kg/m2 Than Those Heathcare—25 Jun 18

Ozempic(R) (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Heathcare—25 Jun 18

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated